Sublimity Therapeutics

About Sublimity Therapeutics

Sublimity Therapeutics, formerly known as Sigmoid Pharma, was a specialty pharmaceutical company focused on developing therapies for gastrointestinal and immunological diseases. Founded in 2003 by Dr. Ivan Coulter, the Dublin-based company aimed to address unmet clinical needs in these areas. Dr. Coulter, who served as CEO until 2018, led the development of the company's proprietary oral drug delivery technology, SmPill®. This platform was designed to enable the oral administration of drugs that are typically difficult to formulate, targeting their release to specific parts of the gastrointestinal tract.

The company's primary business was centered on the research and development of pharmaceutical products, with a business model reliant on venture capital funding and strategic partnerships to advance its drug candidates through clinical trials. A significant milestone was a strategic collaboration with Dr. Falk Pharma for the development and commercialization of its lead product in Europe, which included milestone payments and royalties. In May 2018, Sublimity Therapeutics secured a major financing round of US$64 million, co-led by OrbiMed and Longitude Capital, to fund a global Phase 2b study for its lead drug candidate. At that time, a new management team was appointed, including Anthony J. Giovinazzo as Executive Chairman and Dr. Albert Agro as CEO, both former executives of Cynapsus Therapeutics.

Sublimity's lead product candidate was STI-0529 (formerly CyCol®), an orally delivered formulation of cyclosporine intended for the treatment of moderate to severe ulcerative colitis. Cyclosporine is an immunosuppressive drug used for several inflammatory diseases, but it is not approved for ulcerative colitis. The key feature of STI-0529 was its targeted delivery system, designed to release the drug directly at the site of inflammation in the colon, thereby minimizing systemic absorption and potential side effects associated with conventional cyclosporine. Following the significant funding round, the company received clearance from the FDA, Health Canada, and Ireland's Health Products Regulatory Authority to proceed with its Phase 2b clinical trial. Despite these developments, Sublimity Therapeutics ultimately faced financial difficulties and was liquidated in April 2021.